8-K: Bio-Techne Reports Mixed Q4 Results, Declares Quarterly Dividend

Bio-Techne's fourth quarter results show a slight revenue increase but a decrease in earnings per share, alongside the announcement of a $0.08 per share dividend.

Summary

• Bio-Techne reported a 2% increase in net sales for the fourth quarter of fiscal year 2024, reaching $306.1 million.
• Organic revenue grew by 1% in the fourth quarter and for the full year, reaching $1.2 billion.
• GAAP earnings per share (EPS) for the quarter was $0.25, down from $0.47 in the same quarter last year.
• Adjusted EPS for the quarter was $0.49, compared to $0.55 in the prior year.
• Full year GAAP EPS was $1.05, down from $1.76 the previous year, while adjusted EPS was $1.77, compared to $1.99 last year.
• The Diagnostics & Genomics segment showed strong growth with a 9% organic revenue increase in the fourth quarter and 6% for the full year.
• Cash flow from operations increased by 18% to $299.0 million for the full year.
• The company declared a quarterly dividend of $0.08 per share, payable on August 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to mixed results. While there is positive growth in the Diagnostics & Genomics segment and increased cash flow, the overall decrease in earnings and operating income tempers the positive aspects.

Positives

• The Diagnostics & Genomics segment demonstrated strong growth, with a 9% organic revenue increase in the fourth quarter and 6% for the full year.
• Cash flow from operations increased by 18% for the full year, reaching $299.0 million.
• The company achieved a 33.5% adjusted operating margin in the fourth quarter, showing a 50 basis-point sequential improvement.
• Bio-Techne's management expressed confidence in continued outperformance as life science research end-markets return to historical growth rates.

Negatives

• GAAP EPS decreased to $0.25 per diluted share for the quarter, compared to $0.47 in the same quarter last year.
• Adjusted EPS decreased to $0.49 per diluted share for the quarter, compared to $0.55 in the same quarter last year.
• GAAP operating income for the fourth quarter decreased 52% to $45.8 million.
• Adjusted operating income for the fourth quarter decreased 9% to $101.8 million.
• The Protein Sciences segment experienced a 4% decrease in net sales for the fourth quarter.
• The company's operating margin was negatively impacted by the acquisition of Lunaphore and unfavorable volume leverage within Protein Sciences.

Risks

• The company faces risks related to the integration of new businesses and leadership.
• The introduction and acceptance of new products could impact future results.
• The funding and focus of research by the company's customers could affect demand.
• Increased competition from other biotechnology research product producers could impact pricing.
• General economic conditions, customer site closures, and supply chain issues could pose challenges.
• Currency exchange rate fluctuations could impact financial results.
• The costs and results of research and product development efforts could affect the company's performance.

Future Outlook

Bio-Techne anticipates continued outperformance as life science research end-markets return to historical growth rates, while also focusing on profitability.

Management Comments

• Kim Kelderman, President and Chief Executive Officer, stated he is extremely proud of the team's dedication and execution in stabilizing challenging end-markets.
• Kelderman noted the company achieved another quarter of solid financial results while experiencing continued stabilization in both biopharma and China end-markets.
• Kelderman highlighted the strong performance in the diagnostic product businesses.
• Kelderman expressed confidence in continued outperformance while life science research end-markets return to historical growth rates.

Industry Context

Bio-Techne's results reflect a mixed performance in the life sciences sector, with strong growth in diagnostics and genomics offset by challenges in protein sciences and overall profitability. The company's focus on profitability and strategic growth investments aligns with broader industry trends.

Comparison to Industry Standards

• Bio-Techne's 1% organic revenue growth is below the average growth rate for some of its peers in the life sciences tools and reagents sector, which have seen growth rates in the mid-single digits.
• Companies like Danaher and Thermo Fisher Scientific have reported stronger organic growth in their life sciences segments, although they operate at a larger scale.
• The 9% organic growth in Bio-Techne's Diagnostics and Genomics segment is competitive with other companies focused on spatial biology and diagnostics, such as NanoString Technologies and 10x Genomics.
• Bio-Techne's adjusted operating margin of 33.5% is lower than some of the industry leaders, which often achieve margins in the high 30s or low 40s, indicating room for improvement in operational efficiency.
• The decrease in GAAP EPS and adjusted EPS year-over-year is a concern, as many companies in the sector have been able to maintain or increase profitability despite economic headwinds.

Stakeholder Impact

• Shareholders will receive a dividend of $0.08 per share.
• Employees may be impacted by restructuring and cost-cutting measures.
• Customers will benefit from the company's continued focus on innovation and product development.
• Suppliers may be affected by changes in the company's supply chain and procurement strategies.

Next Steps

• Bio-Techne will host an earnings conference call on August 7, 2024, to discuss the results.
• The Board of Directors will consider future cash dividends on a quarterly basis.

Key Dates

Keywords

Bio-Techne, biotechnology, life sciences, diagnostics, genomics, protein sciences, revenue, EPS, dividend, financial results